CiToxLAB acquires preclinical medical device CRO

According to the company, the acquisition expands its services portfolio to medical devices – with a staff of around 100 people and facilities including operating rooms for cardiac catheterization, state-of-the-art laboratories, a large vivarium, a medical imaging department (scanning and MRI) and clinical pathology and histopathology laboratories.

Dr. Jean-François Le Bigot, Chairman and CEO of CiToxLAB Group said the company identified the preclincical CRO as a “strategic target” to position the group as a “more global services player​.”

“Within CiToxLAB Group, AccelLAB allows the convergence process between the development of new drugs and medical devices which represents a new offer to the customers​,” he said.

Drug development and medical devices​

Several CROs are preparing for this convergence of drug development and medical devices, as they look to expand offerings into the area – most recently demonstrated with CSSI LifeSciences announcement​ yesterday.

The company told us the launch of its fully integrated medical device contract research organization is a “logical extension​” of its life sciences business.

Additionally, the FDA and EMA recently introduced new guidance and regulations for medical devices and medical device/drug combinations.